Skip to main content

Global Biosimilars Market Estimated to See Significant Expansion With 15% CAGR Growth Path 2030

 

The global biosimilars market is set to witness a CAGR of ~15% in the next 5 years. Impending patent expiry of blockbuster biologics, cost containment strategies by governments and payers, rising demand for affordable alternatives for costly biologics, strong regulatory support and clear guidelines, and increased physician and patient acceptance are some of the key factors driving the biosimilars market. 

Biosimilars are biologic medical products that are highly similar to an already approved original biologic (reference product), with no clinically meaningful differences in safety, purity, and effectiveness. The development of biosimilars is complex because, like all biologics, it involves use of living cells and complex manufacturing processes. Therefore, while biosimilars are similar to the reference biologic, they are not identical. The manufacturer must perform an extensive analytical, preclinical, and clinical evaluation to demonstrate similarity. Biosimilars are not just generic alternatives to expensive biologics; instead, they are a viable and reasonable cost alternative to the original biologic, particularly when the reference product's patent has expired. Biosimilars are widely used in the treatment and management of chronic and life-threatening diseases, such as cancer, diabetes, and autoimmune diseases. They help improve access to advanced therapies available globally for patients.

Download a free sample report now 👉
https://meditechinsights.com/global-biosimilars-market/request-sample/

Impending patent expiry of blockbuster biologics to drive market growth

The impending patent expiries of best-selling biologics is a key factor driving growth of the biosimilars market. A major opportunity for cost savings remains untapped, as many high-value biologics nearing the end of patent protection and exclusivity still lack biosimilar development, delaying broader market competition and affordability. These revenue-generating biologics will be losing exclusivity and allowing biosimilar manufacturers to introduce products at lower costs in the biopharmaceutical market. This leads to competitive pricing, increases the number of patients receiving access to biosimilars, and reduction in overall healthcare costs. With most top-selling biologics nearing, if not already passed, patent expiry, companies are investing into biosimilars to take benefit of this opportunity. Regulators have also promoted a favorable environment for biosimilars during this timeframe by updating their approval pathways, leading to an overall acceleration of biosimilar entry into the market when the patent expires.

Strategic partnerships and market consolidation – A key market trend  

Partnerships and market consolidation is a key trend shaping this market as this to decrease development costs, share risks, and launch products in a timely manner. Partnerships involving global pharmaceutical companies and local firms, contract manufacturers/developers, and biotech firms allows them to combine their abilities which helps to gain advanced technology, knowledge of the regulatory pathway, and existing infrastructure network for distribution. For instance, in May 2025 Alvotech expanded its biosimilar partnership with Advanz Pharma and added 3 new biosimilar candidates. Similarly, in July 2024, Evotec SE extended its biosimilar strategic partnership with Sandoz. Furthermore, the mergers and acquisitions taking place in the biosimilar marketplace are facilitating consolidation in the competitive landscape, enabling companies to scale operations and diversify their portfolios. Thus, partnerships can expand their worldwide reach, streamline production processes and support commercialization in the competitive and regulated biosimilar sector.

Competitive Landscape Analysis

The global biosimilars market is marked by the presence of established and emerging market players such as Sandoz Group AG, Pfizer Inc., Amgen Inc., Teva Pharmaceuticals, Inc., Biocon, Eli Lilly and Company, Celltrion Inc., Fresenius SE & Co. KGaA, Samsung Bioepis, and Dr. Reddy’s Laboratories Ltd.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

 Download a sample report for in-depth competitive insights
https://meditechinsights.com/global-biosimilars-market/request-sample/

Global Biosimilars Market Segmentation

This report by Medi-Tech Insights provides the size of the global biosimilars market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application, and manufacturing type.

Market Size & Forecast (2023-2030), By Product, USD Million

  • Monoclonal Antibodies (mAbs)
  • Insulin
  • Granulocyte-Colony Stimulating Factor (G-CSF)
  • Erythropoietin
  • Human Growth Hormone (hGH)
  • Interferons
  • Others

Others Market Size & Forecast (2023-2030), By Application, USD Million

  • Oncology
  • Autoimmune Diseases
  • Diabetes
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Others

Market Size & Forecast (2023-2030), By Manufacturing Type, USD Million

  • In-house Manufacturing
  • Contract Manufacturing

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Digital Pharmaceutical Supply Chain Management Market Sees Increasing Demand with 9% CAGR Until 2030

  The   digital pharmaceutical supply chain management market is projected to grow at a CAGR of 9% from 2025 to 2030.  The growth is driven by the increasing need for enhanced supply chain transparency, demand for temperature-sensitive drug handling, and the shift towards digitization in healthcare operations. However, the high implementation cost and data privacy concerns are notable restraints. The digital pharmaceutical supply chain management includes integration of advanced technologies like AI, blockchain, IoT, and data analytics into the pharmaceutical supply chain. This integration enhances transparency, efficiency, and traceability across sourcing, manufacturing, and distribution processes. The market is vital for ensuring drug safety, mitigating counterfeiting risks, and optimizing logistics. These solutions also aid in regulatory compliance by offering real-time insights and data for reporting. 🔗 Want deeper insights? Download the sample report here: h...
Post a Comment
Read more

Contrast Media APIs Market Evolving Healthcare Needs and Future Business Prospects CAGR 5% by 2030

  The global contrast media APIs market is set to witness a growth rate of 5% in the next 5 years.  Rising volume of diagnostic imaging procedures; technological advancements in imaging modalities; expansion of healthcare infrastructure in emerging markets; rising R&D investments to develop safer and more effective contrast agents, are some of the key factors driving the contrast media APIs market. Contrast media APIs are the primary compounds used in the formulation of contrast agents, which enhance the visibility of internal structures in diagnostic imaging. These APIs play a crucial role in modalities like  computed tomography  (CT),  magnetic resonance imaging  (MRI), and ultrasound by improving the differentiation between tissues, organs, and blood vessels. Typically derived from iodine or gadolinium, they are formulated to ensure solubility, stability, and patient safety during procedures. The manufacturing of contrast media APIs involves stric...
Post a Comment
Read more

Global Healthcare Payer Services Market: AI, Big Data & 8% CAGR Growth Forecast by 2030

  The healthcare payer services market is expected to grow at a CAGR of approximately 8% from 2025 to 2030.  Key drivers include the rising demand for cost-effective healthcare solutions, increased adoption of digital platforms, regulatory changes mandating operational transparency, the surge in healthcare data, and the growing need for fraud prevention mechanisms. However, challenges such as data security concerns and integration complexities act as significant restraints. The healthcare payer services market encompasses a range of administrative, operational, and financial services provided to healthcare payers, including insurance companies, government agencies, and employer groups. These services aim to enhance efficiency, reduce costs, and improve customer satisfaction. Offerings include claims processing, member management, provider management, and analytics for decision-making. The market leverages advanced technologies such as artificial intelligence and cloud compu...
Post a Comment
Read more